(Q38586991)

PubMed publication ID

26371282

4 September 2017

title

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

1 reference

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

Mario E Lacouture

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

author name string

J Naidoo

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

D B Page

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

L C Connell

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

K Schindler

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

M A Postow

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

J D Wolchok

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

publication date

14 September 2015

1 reference

PubMed publication ID

4 September 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

volume

26

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

issue

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

page(s)

2375-2391

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial.

13 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Pembrolizumab versus Ipilimumab in Advanced Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Pembrolizumab for the treatment of non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Toxicity patterns with immunomodulating antibodies and their combinations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

The blockade of immune checkpoints in cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Cancer immunoediting: from immunosurveillance to tumor escape

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Managing immune checkpoint-blocking antibody side effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Toxicities of Immunotherapy for the Practitioner

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

PD-1 regulates germinal center B cell survival and the formation and affinity of long-lived plasma cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Targeting PD-1/PD-L1 interactions for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Disabling immune tolerance by programmed death-1 blockade with pidilizumab after autologous hematopoietic stem-cell transplantation for diffuse large B-cell lymphoma: results of an international phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Nivolumab plus ipilimumab in advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Nivolumab and ipilimumab versus ipilimumab in untreated melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Mechanisms and management of toxicities associated with high-dose interferon alfa-2b therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Safety of Infusing Ipilimumab Over 30 Minutes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Lichenoid dermatitis in three patients with metastatic melanoma treated with anti-PD-1 therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

A case of bullous pemphigoid in a patient with metastatic melanoma treated with pembrolizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Collagen XVII is expressed in malignant but not in benign melanocytic tumors and it can mediate antibody induced melanoma apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Early administration of infliximab for severe ipilimumab-related diarrhea in a critically ill patient.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Ipilimumab-induced acute severe colitis treated by infliximab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Endocrine side effects induced by immune checkpoint inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Cytotoxic T-lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

The emerging toxicity profiles of anti-CTLA-4 antibodies across clinical indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Hepatotoxicity with combination of vemurafenib and ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Pathologic changes in ipilimumab-related hepatitis in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Pulmonary sarcoid-like granulomatosis induced by ipilimumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Organizing pneumonia as a side effect of ipilimumab treatment of melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Inflammatory enteric neuropathy with severe constipation after ipilimumab treatment for melanoma: a case report.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Kidney injuries related to ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Ipilimumab granulomatous interstitial nephritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Immunogenic death of colon cancer cells treated with oxaliplatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Molecular mechanisms of acquired resistance to tyrosine kinase targeted therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Preclinical modeling of EGFR-specific antibody resistance: oncogenic and immune-associated escape mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

A vascular endothelial growth factor receptor-2 inhibitor enhances antitumor immunity through an immune-based mechanism

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Antiangiogenic agents can increase lymphocyte infiltration into tumor and enhance the effectiveness of adoptive immunotherapy of cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Cytokine levels correlate with immune cell infiltration after anti-VEGF therapy in preclinical mouse models of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Combinations of immunotherapy and radiation in cancer therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Immunosuppressive effects of radiation on human dendritic cells: reduced IL-12 production on activation and impairment of naive T-cell priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Ionizing radiation affects human MART-1 melanoma antigen processing and presentation by dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Immunologic correlates of the abscopal effect in a patient with melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Anti-CTLA-4 antibody treatment triggers determinant spreading and enhances murine myasthenia gravis

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) regulates the unfolding of autoimmune diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Ipilimumab in patients with melanoma and autoimmune disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Successful administration of ipilimumab to two kidney transplantation patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Drug-induced graves disease from CTLA-4 receptor suppression

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Neurological immune-related adverse events of ipilimumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDV383

Anti-CTLA4 antibody-induced lupus nephritis

21 January 2018

1 reference

12 December 2020

Ipilimumab associated hepatitis: imaging and clinicopathologic findings

1 reference

12 December 2020

Myasthenia gravis associated with ipilimumab and nivolumab in the treatment of small cell lung cancer

1 reference

12 December 2020

Cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma: a new cause of uveitis

1 reference

12 December 2020

Whole body irradiation; radiobiology or medicine?

1 reference

12 December 2020

Managing toxicities of high-dose interleukin-2.

1 reference

12 December 2020

Successful treatment with Ipilimumab and Interleukin-2 in two patients with metastatic melanoma and systemic autoimmune disease

1 reference

12 December 2020

Acquired resistance of pulmonary adenocarcinoma to initially successful targeted therapy due to EGFR mutation T790M

1 reference

12 December 2020

Identifiers

DOI

10.1093/ANNONC/MDV383

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json

13 May 2020

PubMed publication ID

26371282

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6267867&resulttype=core&format=json